These data support clinical observations that the percentage of HER2/neu + within the tumor and IHC grades of tumors correlate with response to anti-HER2/neu therapy, and demonstrates that our heterogenous tumor model is useful for future studies aimed at developing combination therapies for low or equivocal HER2/neu + tumors. The gene discussed is ERBB2; the disease is neoplasm.